Gossop, M., Marsden, J., Stewart, D., Kidd, T.
The National Treatment Outcome Research Study (NTORS): 4–5 year follow-up results. Addiction
2003; 98: 291–303.
Prescription of heroin for the managment of heroin dependence. CNS Drugs
2009; 23: 463–76.
Strang, J., Groshkova, T., Metrebian, N.
New Heroin-Assisted Treatment: Recent Evidence and Current Practices of Supervised Injectable Heroin Treatment in Europe and Beyond.
European Monitoring Centre for Drugs and Drug Addiction, 2011.
Perneger, TV, Giner, F., del Rio, M., Mino, A.
Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ
1998; 317: 13–8.
Haasen, C., Verthein, U., Degkwitz, P., Berger, J., Krausz, M., Naber, D.
Heroin- assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry
2007; 191: 55–62.
Oviedo-Joekes, E., Brissette, S., Marsh, DC, Lauzon, P., Guh, D., Anis, A., et al Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med
2009; 361: 777–86.
Strang, J., Metrebian, N., Lintzeris, N., Potts, L., Carnwath, T., Mayet, S., et al Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet
2010; 375: 1885–95.
Royal Pharmaceutical Society of Great Britain. British National Formulary 55 (March).
BMJ Group and RPS Publishing, 2008.
Lintzeris, M., Strang, J., Metrebian, N., Byford, S., Hallam, C., Lee, S., et al Methodology for the Randomised Injecting Opioid Treatment Trial (RIOTT): evaluating injectable methadone and injectable heroin treatment versus optimised oral methadone treatment in the UK. Harm Reduct J
2006; 3: 28.
Strang, J., Marsden, J., Cummins, M., Byford, S., Hallam, C., Lee, S., et al Randomized trial of supervised injectable versus oral methadone maintenance: report of feasibility and 6-month outcome. Addiction
2000; 95: 1631–45.
Gordon, L., Tinsley, L., Godfrey, C., Parrott, S.
The economic and social costs of Class A drug use in England and Wales, 2003/04. In Measuring Different Aspects of Problem Drug Use: Methodological Developments (2nd edn) (eds Singleton, N., Murray, R., Tinsley, L.): 41–5. Home Office, 2006.
EuroQol: the current state of play. Health Policy
1996; 37: 53–72.
Richardson, G., Manca, A.
Calculation of quality adjusted life years in the published literature: a review of methodology and transparency. Health Econ
2004; 13: 1203–10.
van der Zanden, BP, Dijkgraaf, MGW, Blanken, P., de Borgie, CAJM, van Ree, JM, Van den Brink, W.
Validity of the EQ-5D as a generic health outcome instrument in a heroin-dependent population. Drug Alcohol Depend
2006; 82: 111–8.
Barrett, B., Byford, S., Crawford, MJ, Patton, R., Drummond, C., Henry, JA, et al Cost-effectiveness of screening and referral to an alcohol health worker in alcohol misusing patients in an accident and emergency department: a decision-making approach. Drug Alcohol Depend
2006; 81: 47–54.
Drummond, M., Sculpher, M., Torrance, GW, O'Brien, B., Stoddart, GL. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, 2005.
Paterson, S., Lintzeris, N., Mitchell, TB, Cordero, R., Nestor, L., Strang, J.
Validation of techniques to detect illicit heroin use in patients prescribed pharmaceutical heroin for the management of opioid dependence. Addiction
2005; 100: 1832–9.
Department of Health. NHS Reference Costs 2008.
Department of Health, 2008.
The Unit Costs of Health and Social Care 2008.
University of Kent at Canterbury, Personal Social Services Research Unit, 2008.
Dubourg, R., Hamed, J.
The Economic and Social Costs of Crime against Individuals and Households 2003/04.
Home Office, 2005.
Metropolitan Police. MPS Ready Reckoner.
Metropolitan Police Authority, 2000.
HM Prison Service. Prison Service Annual Report and Accounts 2008. TSO (The Stationery Office), 2009.
Barber, JA, Thompson, SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med
2000; 19: 3219–36.
Johannesson, M., Weinstein, MC. On the decision rules of cost-effectiveness analysis. J Health Econ
1993; 12: 459–67.
The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ
1999; 18: 341–64.
Fenwick, E., Byford, S.
A guide to cost-effectiveness acceptability curves. Br J Psychiatry
2005; 187: 106–8.
National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. NICE, 2008.
Hjelmgren, J., Berggren, F., Andersson, F.
Health economic guidelines- similarities, differences and some implications. Value Health
2001; 4: 225–50.
Appleby, J., Devlin, N., Parkin, D.
NICE's cost effectiveness threshold: how high should it be?
2007; 335: 359.
Cartwright, WS. Cost-benefit analysis of drug treatment services: review of the literature. J Ment Health Policy Econ
2000; 3: 11–26.
Dijkgraaf, MGW, van der Zanden, BP, de Borgie, CAJM, Blanken, P., van Ree, JM, Van den Brink, W.
Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. BMJ
2005; 330: 1297–302.
Home Office. A New Approach to Fighting Crime.
Home Office, 2011.
A note on the depreciation of the societal perspective in economic evaluation of health care. Health Policy
1995; 33: 59–66.
Chambers, J., Yiend, J., Barrett, B., Burns, T., Doll, H., Fazel, S., et al Outcome measures used in forensic mental health research: a structured review. Crim Behav Ment Health
2009; 19: 9–27.